Bristol Myers Squibb Company $BMY Shares Newly Bought by B.A. Schrock Wealth Management Inc.

B.A. Schrock Wealth Management Inc. acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 65,007 shares of the biopharmaceutical company’s stock, valued at approximately $3,995,000. Bristol Myers Squibb accounts for approximately 1.3% of B.A. Schrock Wealth Management Inc.’s portfolio, making the stock its 23rd biggest position.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BMY. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $27,000. Bayban purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $31,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $32,000. Groupe la Francaise raised its position in shares of Bristol Myers Squibb by 562.9% during the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 501 shares during the period. Finally, Arlington Trust Co LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on BMY shares. Royal Bank Of Canada upped their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. JPMorgan Chase & Co. boosted their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Roth Capital started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price objective for the company. Guggenheim reiterated a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $64.88.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.05% of the stock is owned by company insiders.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Pipeline progress provided the main catalyst. Bristol Myers reported favorable Phase 3 results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including improved progression-free survival. The data may support upcoming regulatory discussions and strengthen the company’s growth outlook as older blockbuster drugs face competitive pressure. What Could Bristol Myers Squibb BMY Two Phase 3 Wins Change?
• Positive Sentiment: Analyst support remains a tailwind. Truist Financial maintained its Buy rating on BMY, signaling confidence in the company’s pipeline and valuation. Bristol Myers’ relatively low earnings multiple and sizeable dividend yield may also attract income-oriented investors. Truist Financial Sticks to Its Buy Rating for Bristol Myers Squibb
• Neutral Sentiment: Admilparant results were characterized inconsistently. Reports described the Phase 3 idiopathic pulmonary fibrosis data as either positive or mixed, with favorable efficacy and safety observations but some limitations that could affect regulatory expectations. The conflicting interpretation makes the drug a potential opportunity but not yet a clear near-term catalyst. BMY Reports Mixed Phase III Trial Results
• Neutral Sentiment: Investor attention is elevated ahead of quarterly earnings. BMY is scheduled to report third-quarter results later this month, with analysts expecting a single-digit decline in earnings. Recent trial news and the stock’s strong longer-term performance have increased focus on whether results and guidance can support the valuation. Bristol Myers Squibb Quarterly Earnings Preview
• Negative Sentiment: Wells Fargo reduced its price target from $65 to $60 and kept an Equal Weight rating. The lower target reflects limited perceived upside and highlights ongoing concerns about earnings growth, patent-related pressure and the need for newer medicines to replace aging blockbusters. Wells Fargo Lowers Bristol Myers Squibb Price Target

Bristol Myers Squibb Stock Up 4.7%

Shares of BMY opened at $59.34 on Thursday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock has a market capitalization of $121.22 billion, a price-to-earnings ratio of 13.07, a price-to-earnings-growth ratio of 0.28 and a beta of 0.19. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The business’s 50 day simple moving average is $63.72 and its 200-day simple moving average is $60.28.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period last year, the firm posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.70 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.